Insurers face long road, high coverage cost
Novo Nordisk’s obesity drug Wegovy slashed the risk of serious heart problems by 20% in a large clinical trial. That landmark finding could put more pressure on U.S. insurers to cover the blockbuster medication and similar weight loss treatments. But organizations representing insurers emphasized that the data is still preliminary, and concerns remain about the … Read more